Celgene Shares Higher On Positive Crohn’s Patient Data
Celgene Corporation CELG 0.45% shares are up a modest 1.2 percent in Mondays session after the company’s United European Gastroenterology Week (UEGW) abstract revealed wide-spread activity for mongersen (GED-301) among Crohn’s patients.